Expert physician-scientists and clinicians review those combinations of novel target agents classic chemotherapies that hold the most promise for the future of medical oncology, and detail their optimal sequence, pharmacokinetic interactions, and interaction with downstream cellular signals. The combinations run the gamut of targeted therapies against cell surface receptors (EGF-R and HER2), the cell cycle (the CDKs), signal transduction events (PKC and NF-kB), apoptosis (bcl-2), as well as focused therapies in ovarian cancer, hematologic diseases, and breast cancer. The authors emphasize novel translational approaches that are rapidly moving from the laboratory bench top to the patient's bedside for the future treatments in cancer therapy.
Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.
Early clinical trials of the new molecular-based anticancer agents have shown that many are marginal in controlling cancer, but prove to be potent modulators and potentiators of chemotherapy-induced apoptosis when used in combination with classic cytotoxic drugs or radiation. In Combination Cancer Therapy: Modulators and Potentiators, expert physician-scientists and clinicians with first-hand experience in the clinical development of targeted therapies review those combinations that hold the most promise for the future of medical oncology, detailing their optimal sequence, pharmacokinetic interactions, and interaction with downstream cellular signals. The combinations run the gamut of targeted therapies against cell surface receptors (EGF-R and HER2), the cell cycle (the CDKs), signal transduction events (PKC and NF-kB), apoptosis (bcl-2), as well as focused therapies in ovarian cancer, hematologic diseases, and breast cancer. The authors emphasize novel translational approaches that are rapidly moving from the laboratory benchtop to the patient's bedside as a new generation of cancer therapeutics.
Cutting-edge and forward-looking, Combination Cancer Therapy: Modulators and Potentiators offers everyone in the fields of cancer drug development and therapy a powerful new understanding of the optimal sequencing and scheduling of new combination drug therapies necessary to maximize the effects for cancer patients today.
„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.
Anbieter: Brook Bookstore On Demand, Napoli, NA, Italien
Zustand: new. Questo è un articolo print on demand. Bestandsnummer des Verkäufers NNOGXNQKGP
Anzahl: Mehr als 20 verfügbar
Anbieter: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Deutschland
Taschenbuch. Zustand: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Expert physician-scientists and clinicians review those combinations of novel target agents classic chemotherapies that hold the most promise for the future of medical oncology, and detail their optimal sequence, pharmacokinetic interactions, and interaction with downstream cellular signals. The combinations run the gamut of targeted therapies against cell surface receptors (EGF-R and HER2), the cell cycle (the CDKs), signal transduction events (PKC and NF-kB), apoptosis (bcl-2), as well as focused therapies in ovarian cancer, hematologic diseases, and breast cancer. The authors emphasize novel translational approaches that are rapidly moving from the laboratory bench top to the patient's bedside for the future treatments in cancer therapy. 296 pp. Englisch. Bestandsnummer des Verkäufers 9781627038065
Anzahl: 2 verfügbar
Anbieter: Ria Christie Collections, Uxbridge, Vereinigtes Königreich
Zustand: New. In. Bestandsnummer des Verkäufers ria9781627038065_new
Anzahl: Mehr als 20 verfügbar
Anbieter: moluna, Greven, Deutschland
Zustand: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Expert physician-scientists and clinicians review those combinations of novel target agents classic chemotherapies that hold the most promise for the future of medical oncology, and detail their optimal sequence, pharmacokinetic interactions, and interactio. Bestandsnummer des Verkäufers 11781726
Anzahl: Mehr als 20 verfügbar
Anbieter: Kennys Bookshop and Art Galleries Ltd., Galway, GY, Irland
Zustand: New. Editor(s): Schwartz, Gary K. Series: Cancer Drug Discovery and Development. Num Pages: 294 pages, biography. BIC Classification: MJCL. Category: (G) General (US: Trade). Dimension: 235 x 155 x 16. Weight in Grams: 456. . 2014. Paperback. . . . . Bestandsnummer des Verkäufers V9781627038065
Anzahl: 15 verfügbar
Anbieter: preigu, Osnabrück, Deutschland
Taschenbuch. Zustand: Neu. Combination Cancer Therapy | Modulators and Potentiators | Gary K. Schwartz | Taschenbuch | Cancer Drug Discovery and Development | x | Englisch | 2014 | Humana | EAN 9781627038065 | Verantwortliche Person für die EU: Humana Press in Springer Science + Business Media, Heidelberger Platz 3, 14197 Berlin, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu. Bestandsnummer des Verkäufers 104986929
Anzahl: 5 verfügbar
Anbieter: buchversandmimpf2000, Emtmannsberg, BAYE, Deutschland
Taschenbuch. Zustand: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Expert physician-scientists and clinicians review those combinations of novel target agents classic chemotherapies that hold the most promise for the future of medical oncology, and detail their optimal sequence, pharmacokinetic interactions, and interaction with downstream cellular signals. The combinations run the gamut of targeted therapies against cell surface receptors (EGF-R and HER2), the cell cycle (the CDKs), signal transduction events (PKC and NF-kB), apoptosis (bcl-2), as well as focused therapies in ovarian cancer, hematologic diseases, and breast cancer. The authors emphasize novel translational approaches that are rapidly moving from the laboratory bench top to the patient's bedside for the future treatments in cancer therapy.Humana Press in Springer Science + Business Media, Heidelberger Platz 3, 14197 Berlin 296 pp. Englisch. Bestandsnummer des Verkäufers 9781627038065
Anzahl: 1 verfügbar
Anbieter: Books Puddle, New York, NY, USA
Zustand: New. Bestandsnummer des Verkäufers 26357400724
Anzahl: 4 verfügbar
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Taschenbuch. Zustand: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Expert physician-scientists and clinicians review those combinations of novel target agents classic chemotherapies that hold the most promise for the future of medical oncology, and detail their optimal sequence, pharmacokinetic interactions, and interaction with downstream cellular signals. The combinations run the gamut of targeted therapies against cell surface receptors (EGF-R and HER2), the cell cycle (the CDKs), signal transduction events (PKC and NF-kB), apoptosis (bcl-2), as well as focused therapies in ovarian cancer, hematologic diseases, and breast cancer. The authors emphasize novel translational approaches that are rapidly moving from the laboratory bench top to the patient's bedside for the future treatments in cancer therapy. Bestandsnummer des Verkäufers 9781627038065
Anzahl: 1 verfügbar
Anbieter: Kennys Bookstore, Olney, MD, USA
Zustand: New. Editor(s): Schwartz, Gary K. Series: Cancer Drug Discovery and Development. Num Pages: 294 pages, biography. BIC Classification: MJCL. Category: (G) General (US: Trade). Dimension: 235 x 155 x 16. Weight in Grams: 456. . 2014. Paperback. . . . . Books ship from the US and Ireland. Bestandsnummer des Verkäufers V9781627038065
Anzahl: 15 verfügbar